US Edition
Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma
- Myosin Therapeutics announced on June 9, 2025, that the FDA accepted its IND application to start a first-in-human trial of MT-125 for glioblastoma in Jupiter, Florida.
- This clearance followed Myosin's rapid program development with Mayo Clinic to address glioblastoma, an aggressive, treatment-resistant cancer with limited advances in two decades.
- MT-125 selectively inhibits non-muscle myosin II, a protein driving tumor growth, therapy resistance, oxidative stress, and immune evasion, targeting patients with poor chemotherapy responsiveness.
- The drug has Orphan Drug Designation and showed potent preclinical anti-tumor activity while enhancing radiotherapy efficacy, with Valerie Ahmuty noting the FDA's "rapid and comprehensive review."
- The FDA acceptance enables a Phase 1 trial combining MT-125 with standard radiation in newly diagnosed glioblastoma patients, highlighting a critical step toward potential new treatment options.
Insights by Ground AI
Does this summary seem wrong?
29 Articles
29 Articles
All
Left
1
Center
9
Right
3
Bennington Banner+28 Reposted by 28 other sources
Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma
JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for…
Coverage Details
Total News Sources29
Leaning Left1Leaning Right3Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
C 69%
R 23%
Factuality
To view factuality data please Upgrade to Premium
